Anti-parstatin promotes angiogenesis and ameliorates left ventricular dysfunction during pressure overload

International Journal of Biomedical Science

Volumn 10, Issue 1, 2014, Pages 1-7

  Givvimani, Srikanth ^a   Narayanan, Nithya ^a   Pushpakumar, Sathnur Basappa ^a   Tyagi, Suresh C ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Angiogenesis; Anti angiogenic factors; Aortic banding; Heart failure; Matrix remodeling

Indexed keywords

ANGIOGENESIS INHIBITOR; CASPASE; CD31 ANTIGEN; GELATINASE A; GELATINASE B; PARSTATIN ANTIBODY; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASCENDING AORTA SURGERY; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ENZYME INHIBITION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE OVERLOAD; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 84897867897     PISSN: 15509702     EISSN: 15552810     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Givvimani S, et al. Hydrogen sulfide mitigates transition from compensatory hypertrophy to heart failure. J. Appl. Physiol. 2011; 110 (4): 1093-1100.
2. Givvimani S, et al. MMP-2/TIMP-2/TIMP-4 versus MMP-9/TIMP-3 in transition from compensatory hypertrophy and angiogenesis to decompensatory heart failure. Arch. Physiol Biochem. 2010; 116 (2): 63-72.
3. Shiojima I, et al. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J. Clin. Invest. 2005; 115 (8): 2108-2118.
4. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996; 86 (3): 353-364.
5. Ferrara N, et al. Targeting VEGF-A to treat cancer and age-related macular degeneration. Annu. Rev. Med. 2007; 58: 491-504.
6. Ribatti D. Endogenous inhibitors of angiogenesis: a historical review. Leuk Res. 2009; 33 (5): 638-644.
7. Sodha NR, et al. Endostatin and angiostatin are increased in diabetic patients with coronary artery disease and associated with impaired coronary collateral formation. Am. J. Physiol Heart Circ. Physiol. 2009; 296 (2): H428-H434.
8. Givvimani S, et al. Mitochondrial division/mitophagy inhibitor (Mdivi) ameliorates pressure overload induced heart failure. PLOS One. 2012; 7 (3): e32388.
9. Zania P, et al. Parstatin, the cleaved peptide on proteinase-activated receptor 1 activation, is a potent inhibitor of angiogenesis. J. Pharmacol Exp. Ther. 2009; 328 (2): 378-389.
10. Ma L, et al. Proteinase-activated receptors 1 and 4 counter-regulate endostatin and VEGF release from human platelets. Proc. Natl. Acad. Sci. USA. 2005; 102 (1): 216-220.
11. Yin YJ, et al. Oncogenic transformation induces tumor angiogenesis: a role for PAR1 activation. FASEB J. 2003; 17 (2): 163-174.
12. Strande JL, et al. Parstatin: a cryptic peptide involved in cardioprotection after ischaemia and reperfusion injury. Cardiovasc Res. 2009; 83 (2): 325-334.
13. Routhu KV, Tsopanoglou NE, Strande JL. Parstatin(1-26): the putative signal peptide of protease-activated receptor 1 confers potent protection from myocardial ischemia-reperfusion injury. J. Pharmacol Exp. Ther. 2010; 332 (3): 898-905.
14. Huang H, et al. Parstatin suppresses ocular neovascularization and inflammation. Invest Ophthalmol Vis. Sci. 2010; 51 (11): 5825-5832.
15. Rottman JN, Ni G, Brown M. Echocardiographic evaluation of ventricular function in mice. Echocardiography. 2007; 24 (1): 83-89.
16. Qipshidze N, et al. Hydrogen sulfide mitigates cardiac remodeling during myocardial infarction via improvement of angiogenesis. Int. J. Biol. Sci. 2012; 8 (4): 430-441.
17. Ramachandran R, et al. Release of the thrombin receptor (PAR-1) N-terminus from the surface of human platelets activated by thrombin. Thromb Haemost. 1997; 78 (3): 1119-1124.
18. Furman MI, et al. The cleaved peptide of PAR1 results in a redistribution of the platelet surface GPIb-IX-V complex to the surface-connected canalicular system. Thromb Haemost. 2000; 84 (5): 897-903.
19. Even-Ram S, et al. Thrombin receptor overexpression in malignant and physiological invasion processes. Nat. Med. 1998; 4 (8): 909-914.
20. Ellis CA, et al. Thrombin induces proteinase-activated receptor-1 gene expression in endothelial cells via activation of Gi-linked Ras/ mitogen-activated protein kinase pathway. J. Biol. Chem. 1999; 274 (19): 13718-1327.
21. Kaushal V, et al. Thrombin receptor expression is upregulated in prostate cancer. Prostate. 2006; 66 (3): 273-282.
22. Darmoul D, et al, Aberrant expression and activation of the thrombin receptor protease-activated receptor-1 induces cell proliferation and motility in human colon cancer cells. Am. J. Pathol. 2003; 162 (5): 1503-1513.
23. Shah R. Protease-activated receptors in cardiovascular health and diseases. Am. Heart J. 2009; 157 (2): 253-262.